Novartis trims again with $390m drugs sale to RecordatiNovartis has been streamlining its business since CEO Vas Narasimhan took over, and has continued that push with Share XNovartis trims again with $390m drugs sale to Recordatihttps://pharmaphorum.com/news/novartis-trims-again-with-390m-drugs-sale-to-recordati/
AZ sells anaesthetics rights to AspenSouth African firm will pay $770 million. Share XAZ sells anaesthetics rights to Aspenhttps://pharmaphorum.com/news/az-sell-rights-anaesthetics-pharmacare/